RVMDRevolution Medicines, Inc.Finished
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 47 (final count)
- Started
- Dec 30, 2021
- Main results expected
- Jul 3, 2024
- Fully finished
- Aug 29, 2024
- Results posted
- Jan 6, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) as Assessed Per RECIST v1.1
Measured over: 31 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05054725 · record last updated 2026-01-06 · checked 2026-11-09 15:47 UTC